Detalhe da pesquisa
1.
Surgical Management and Long-Term Outcomes of BIA-ALCL: A Multidisciplinary Approach.
Ann Surg Oncol
; 31(3): 2032-2040, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38102324
2.
Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma.
Blood
; 140(8): 851-860, 2022 08 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35679476
3.
Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study.
Haematologica
; 109(1): 209-219, 2024 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37439343
4.
Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good longterm outcomes.
Haematologica
; 109(1): 200-208, 2024 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646672
5.
Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era.
Blood
; 137(1): 39-48, 2021 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32730585
6.
A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas.
Blood
; 138(26): 2828-2837, 2021 12 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34653242
7.
Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study.
Haematologica
; 108(3): 822-832, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36263843
8.
Central nervous system lymphomas-Assessment and treatment and prevention of central nervous system relapse.
Hematol Oncol
; 2023 Jun 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37381737
9.
Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study.
Cancer
; 128(8): 1595-1604, 2022 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35157306
10.
Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B-cell lymphoma.
Haematologica
; 107(5): 1131-1143, 2022 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34162177
11.
An Updated Approach and Understanding of Breast Implant-Associated Anaplastic Large Cell Lymphoma.
J Natl Compr Canc Netw
; 20(3): 309-315, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35276670
12.
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 20(3): 285-308, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35276674
13.
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study.
Haematologica
; 105(6): 1604-1612, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31537689
14.
ASO Author Reflections: Approaching BIA-ACL Diagnosis and Treatment.
Ann Surg Oncol
; 31(4): 2789-2790, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38324236
15.
Predictors of cardiovascular outcome and rehospitalization in elderly patients with heart failure.
Eur J Clin Invest
; 49(2): e13044, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30368802
16.
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi.
Biol Blood Marrow Transplant
; 24(9): 1814-1822, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29857196
17.
Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas.
Blood
; 127(7): 858-68, 2016 Feb 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-26603836
18.
Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies.
Blood
; 138(9): 811-814, 2021 09 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34189565
19.
Bone marrow biopsies do not impact response assessment for follicular lymphoma patients treated on clinical trials.
Br J Haematol
; 179(2): 242-245, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28677889
20.
Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
Oncologist
; 21(9): 1107-12, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27382029